Pfanstiehl Solutions for High-Concentration Antibody Formulations

By Pfanstiehl

The development of high-concentration antibody formulations (HCAFs) of greater than 100mg/ml is essential for the creation of monoclonal antibody (mAb) therapies that can be delivered subcutaneously.

However, inevitable variability between molecules creates complex technical challenges that requires a broad set of tools and expertise to solve.

To read more, please download this free white paper.

Enter your details below to view the free white paper

By downloading this whitepaper, you acknowledge that GlobalData may share your information with our white paper partners/sponsors who may contact you directly with information on their products and services.

Visit our Privacy Policy for more information about our services, how GlobalData may use, process and share your personal data, including information on your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.